

Review

Not peer-reviewed version

---

# Epigenetic Alterations Induced by Smoking: Applications of Artificial Intelligence in Understanding and Preventing Addiction: A Comprehensive Review

---

[Edith-Simona Ianosî](#) , [Daria Maria Tomoroga](#) <sup>\*</sup> , [Anca-Meda Văsieşiu](#) , [Bianca Liana Grigorescu](#) , [Mara Vultur](#) , [Maria Beatrice Ianosî](#)

Posted Date: 24 September 2025

doi: 10.20944/preprints202509.2065.v1

Keywords: Epigenetic inheritance; DNA methylation; histone modification; non-coding RNA; transgenerational respiratory disease; artificial intelligence



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

# Epigenetic Alterations Induced by Smoking: Applications of Artificial Intelligence in Understanding and Preventing Addiction: A Comprehensive Review

Ianosi Edith-Simona <sup>1,†</sup>, Tomoroga Daria-Maria <sup>2,\*†</sup>, Văsieșiu Anca-Meda <sup>3</sup>, Grigorescu Bianca-Liana <sup>4</sup>, Vultur Mara <sup>1</sup> and Ianosi Maria-Beatrice <sup>5</sup>

<sup>1</sup>. Department of Pulmonology, University of Medicine, Pharmacy, Science and Tehnology of Târgu-Mureș, 540139 Târgu Mures, Romania

<sup>2</sup>. University of Medicine, Pharmacy, Science and Tehnology of Târgu-Mureș, 540139 Târgu Mures, Romania

<sup>3</sup>. Department of Infectious Disease, University of Medicine, Pharmacy, Science and Tehnology of Târgu-Mureș, 540139 Târgu Mures, Romania

<sup>4</sup>. Anaesthesiology and Intensive Care, University of Medicine, Pharmacy, Science and Tehnology of Târgu-Mureș, 540139 Târgu Mures, Romania

<sup>5</sup>. Clinic of Pulmonology, County Hospital Mures, 540011 Târgu Mures, Romania

\* Correspondence: tomoroga.daria-maria.24@stud.umfst.ro

† These authors have equal contributions.

## Abstract

**Introduction:** Cigarette smoking is unquestionably associated with an increase in morbidity and mortality worldwide, exerting significant adverse effects on respiratory health. It has become apparent that the impact of tobacco persists within the genome even long after cessation of smoking. Furthermore, the offspring of smokers may also be affected by the detrimental effects of smoking. **Material and method:** The modifications made to the body, such as DNA methylation, histone modification, and regulation by non-coding RNAs, do not change the DNA sequence but can influence gene expression. In respiratory disease, the transgenerational effects of smoking are associated with an increased risk of asthma or COPD and decreased lung function in offspring, despite them not being exposed to smoke. Prenatal nicotine exposure leads to pulmonary pathology that persists across three consecutive generations, supported by animal studies conducted by Rehan et al. Significant advances in high-throughput genomic and epigenomic technologies have enabled the discovery of molecular phenotypes. These either reflect or are influenced by them. Due to the hidden environmental effects and the rise of artificial intelligence (AI) in this domain, we now have the means to develop models that explain complex data related to disease risk. By compiling the latest research on how smoking affects gene function and structure, we emphasise how tobacco can increase vulnerability to multiple diseases. **Discussion:** For many years, it was widely believed that diseases are solely inherited through genetics. However, recent research in epigenetics has led to a significant realisation: environmental factors play a crucial role in an individual's life. External influences leave a mark on DNA that can influence future health and offer insights into potential illnesses. In this context, it is possible that in the future, doctors might treat people not as a whole but as individual beings, with personalised medication, tests, and other approaches. **Conclusions:** The accumulated evidence suggests that exposure to various environmental factors has a significant impact on transgenerational gene expression patterns, which may contribute to the development of multiple diseases. The application of artificial intelligence in this domain is currently a crucial tool for researching potential future health issues in individuals, and it holds a powerful prospect that could transform medicine as we know it.

**Keywords:** Epigenetic inheritance; DNA methylation; histone modification; non-coding RNA; transgenerational respiratory disease; artificial intelligence

---

## Introduction

Indirect or passive smoke exposure causes about 1.3 million of the roughly 8 million tobacco-related deaths globally each year [1].

Alongside a growing recognition of the generational consequences, tobacco smoking has nocive effects on the respiratory, cardiovascular, and vascular systems, and not only. The concept of disease pathophysiology has advanced significantly by exposing the toxicological relationships that reveal the cause-and-effect relationship between diseases caused by tobacco use and the organism, with the biological basis lying in epigenetic inheritance [the inheritance of phenotypic traits through molecular mechanisms without involving DNA sequence] [2].

In fact, population-based studies have documented epigenetic changes in response to various environmental factors, including nutrition, psychological stress, pollutants, and tobacco smoke. All of these approaches can induce epigenetic modifications to DNA itself (DNA methylation) or its associated histone proteins [chromatin remodelling] [3]. Additionally, a small number of epigenetic marks can evade the widespread reset during gametogenesis and early embryonic development, allowing them to be inherited across generations [4].

Asthma and COPD have traditionally been viewed as the result of a combination of genetic susceptibilities and an array of environmental exposures. Longitudinal animal models and human studies confirm that the phenotypes relevant to respiratory outcomes in progeny can be influenced by epigenetic mechanisms established through exposure of ancestors to environmental influences [5,6]. This affirmation highlights the fact that a future improvement of public health strategies should include the dissemination of knowledge regarding the molecular determinants of environmental risk.

## Material and Method

We designed this review as an integrative synthesis, aiming not only to compile the literature but also to critically examine the epistemic ideas underlying contemporary research on the epigenetics of smoking and its connection with machine learning models [7].

The methodological ambition of the paper was to capture all the crucial details of a systematic review, while keeping an open perspective about the prospects.

To ensure comprehensive coverage, searches were conducted in biomedical databases to identify peer-reviewed studies, systematic reviews, and multiple research articles on the epigenetics of smoking, its effects on the organism, and the intersection of this field with the era of artificial intelligence. Clinical terms [e.g., COPD, asthma], molecular descriptors [DNA methylation, histone acetylation], and computational vocabulary [machine learning, artificial intelligence] were integrated to create overlapping domains, enhancing the interdisciplinary connection between these fields and emphasising the relationship that has developed between these disciplines [8]

## Quality and Eligibility Appraisal

Apart from the usual criteria, the selected studies underwent a review of their methodological quality. Priority was given to longitudinal and multigenerational designs, which enable inference of inheritance patterns [9]. Additionally, we identified whole-genome or high-throughput findings that reflect changes across the entire epigenome rather than at single loci [10], and materials that demonstrate the capacity of AI technologies to scan and search the epigenome for variations that cause diseases [11–13].

## Methodological Framework

The methodology employed in this research focuses on the scientific understanding that epigenetic inheritance and AI are increasingly interconnected areas of study with the potential to transform the world as we know it. This focused approach was undertaken to produce a descriptive review, as well as to develop a critical repertoire that highlights the importance of the current knowledge in this field, which must be integrated into everyday medicine for the prediction and prevention of diseases [14].

Literature was identified, assessed, and categorised according to the primary biological and computational sub-fields outlined in the paper: DNA methylation, histone modification, non-coding RNAs, experimental animal studies, paternal epigenetic transmission, and the application of artificial intelligence to identify epigenetic signatures.

## Smoking-associated Respiratory Diseases Caused by Epigenetic Mechanisms

Tobacco has a pathobiologically harmful effect rather than simply being unfavourable to health. Cigarette smoke is composed of more than 7000 chemical compounds, including heavy metals, nitrosamines, and polycyclic aromatic hydrocarbons [PAHs], acting as potent epigenetic modulators. This allows these agents to directly affect the activity of various enzymatic systems that regulate DNA methylation, histone modification, and chromatin structure [15,16].

### DNA Methylation

DNA methylation involves the covalent addition of methyl groups to cytosine bases, mainly occurring on CpG islands. It is one of the most vital strategies for altering gene expression without modifying the DNA sequence [17]. Methylation generally takes place in promoter regions, where it silences the gene associated with that region. A subset of gene promoters in the airway epithelium of smokers shows both increased and decreased methylation. While hypermethylation can lead to gene silencing and tumour suppression, hypomethylation may cause genomic instability and cancer-specific changes [18]. Some of these alterations can increase the patient's risk of lung cancer or breathing issues.

What is most interesting is that germline cells (sperm and oocytes) have the same methylation pattern. In other words, such epigenetic modifications may be inherited [19]. Studies have also suggested that if a mother smokes while pregnant, the offspring may suffer from epigenetic changes, depending on where the affected genes are located [which could relate to abnormal methylation]. This reveals that smoking could not only be bad for the smoker, but also for their progeny and generations to come.

Significantly, inflammation-related, airway remodelling, and pulmonary function-associated genes were found to be differentially methylated. Examples include ADAM33 [20], IL13 [21], and SERPINA1 [22]. The long-lasting memory of ancestral exposure is carried both by the exposed individuals themselves and in their descendants, the latter of whom were never exposed to the toxicants [23,24].

In a large Lifelines cohort, grandchildren of women who smoked during pregnancy exhibited altered DNA methylation at asthma-related loci, even if their parents did not smoke. The results suggest that methylation changes caused by smoking can have long-lasting effects on disease risk through mechanisms that are yet to be identified [25].

It is increasingly likely that the seemingly transient gene expression changes in response to smoking-induced methylation are actually a crucial epigenetic pattern and can predispose later generations to respiratory illness. This information is vital from a public health perspective because it illustrates how tobacco use results in transgenerational effects. This is something to keep in consideration when establishing policies that are meant to lower smoking rates [26]

### Histone Modifications

These proteins bind to DNA and assemble into larger structures called nucleosomes, the fundamental physical units of chromatin. These histones can be acetylated, methylated, or phosphorylated, and this changes how densely packed the DNA is. Loose chromatin structure permits more unrestricted access to genes, resulting in enhanced gene expression. Loose chromatin allows more access to transcription machinery, which increases the activity of gene expression. Loose chromatin means that the transcription machinery can reach out to genes in a more straightforward manner, producing a more active gene expression.


It has been shown that tobacco smoke causes the acetylation of histone H3 at lysine 9 in airway epithelial cells, thereby promoting the activation of pro-inflammatory genes and leading to a chronic inflammatory state in the lung [27]. It is essential to highlight recent research findings: changes in histones are not merely somatic-specific, and the modifications that germline cells undergo can survive the extensive epigenetic reprogramming after fertilisation. These changes can influence gene expression during lung development in the offspring and even in subsequent generations, if they persist [28]. This idea offers yet another way in which smoking-induced damage could be biologically 'regarded' and transmitted, affecting respiratory health long after the initial exposure.

### Non-Coding RNA Regulation

Non-coding RNAs, representing a significant number of transcripts found in mammalian cells, include long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), which are key elements in regulating gene activity at the post-transcriptional level following the generation of prototypical RNA from a gene [29]. They are also capable of serving as molecular fine-tuners to ensure that proteins are produced at the appropriate time and in the correct quantity.

Cigarette smoke can disrupt this balance by influencing miRNA expression related to inflammation and alterations in lung tissue structure [30]. The presence of smoke near the lungs may elevate levels of miR-223 and miR-21, two signalling molecules that regulate pathways determining airway responsiveness [to inhaled irritants, allergens, or inflammatory signals] and the extent of scar tissue formation. If these expression patterns occur in cells that produce germline cells, the transmission of this affected lineage could result in the next two generations being born with abnormal transcortical and pneumological reactions [31].

### The Rehan et al. Study



**Figure 1.** The illustration shows the experimental approach and results of Rehan et al. The F0 generation received nicotine (the first two groups) or a combination of nicotine and rosiglitazone (the last one). The lungs and gonads of male and female offspring (F1 generation) display epigenetic changes, with the lungs showing an asthma-like

functional phenotype (blue nicotine-induced modifications). The offspring of mice treated with nicotine and rosiglitazone do not show these nicotine effects. The F2 generation, the offspring of F1 mated pairs, demonstrates similar nicotine-induced changes in lung function as their ancestors, despite not being exposed to the substance [35].

Besides the common knowledge that maternal smoking during pregnancy has a significant effect on the development of the fetus, leading to cardiac problems and low birthweight [32,33], experimental evidence in rodents provides strong support for the

hypothesis that in utero exposure to nicotine can produce transgenerational alterations of lung structure and function. Rehan et al. described a groundbreaking rat study, which demonstrated impaired lung function and the adverse effects that smoke exposure has had across generations [34]. For the F1 offspring, gestational nicotine exposure led to decreased alveolar surface area and increased pulmonary structural abnormalities, such as thickened alveolar septa with prominent collagen deposition and impaired elastin fibre assembly [34]. Additionally, suppression of peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ) signalling, a pathway essential for normal alveolar development, occurs alongside these changes. Remarkably, when the F1 offspring (which had never been exposed to nicotine after birth) were bred, their next generation [F2] also developed similar pulmonary pathology. However, there was no direct exposure to nicotine during their own gestation [34]. This suggests that the phenotypes observed were transmitted via the germline, most likely through heritable, stable epigenetic modifications rather than DNA sequence changes.

The interpretation that epigenetic responses are transmitted from sperm to offspring and through germline passage in a transgenerational manner is emphasised in Leslie's review of multigenerational nicotine effects. The article highlights the persistence of epigenetics across generations, suggesting that nicotine-induced epigenetic changes can evade both significant reprogramming waves – first during gametogenesis and then in early embryo [35]. These stable marks – which may include DNA methylation, histone modifications, and changes in non-coding RNA profiles – serve as a 'molecular memory' or legacy of environmental exposure that influences the development of lung remodelling episodes many years after the initial exposure.

Notably, Rehan et al. have demonstrated that pharmacological activation of PPAR- $\gamma$  during gestational nicotine exposure prevents both the structural lung defects in directly exposed offspring and their inheritance in the F2 generation (Figure1).

Each of these results provides the first evidence in a mouse model that specific molecular abnormalities contribute to the gene-environment interactions underlying the transgenerational inheritance of pulmonary morbidity, collectively highlighting a key principle of this study. Tracking complex environmental events through equally detailed molecular marks in germ cells can significantly influence susceptibility to diseases among offspring who have never themselves been exposed to a particular harmful agent [34,35].

## Paternal Smoking and Epigenetic Transmission

Emerging evidence has further illustrated how paternal influences, notably smoking, can epigenetically program the developing placenta and thereby affect fetal health in later life. Bhadsavle and Golding [2022] [36] have published compelling rodent data demonstrating that paternal stressors can epigenetically modify sperm, especially impacting imprinted genes vital for placental development and fetal growth. These sperm-borne epigenetic marks were shown to disrupt placental architecture, leading to significant alterations in trophoblastic zones and histological organisation; thus, making the offspring susceptible to metabolic, developmental, and respiratory dysfunctions.

Similarly, Vlachou et al. [2025] demonstrated that smoking by parents, or even grandparents, results in inheritable changes mainly through alterations in DNA methylation affecting germ cells and placental tissues, thereby modulating susceptibility not only to early-onset respiratory problems but also to metabolic diseases [37].

## AI in Epigenetics

Artificial intelligence [AI] has reached the field of biomedical research and has undoubtedly been a game-changer. In combination with epigenetics, it has recently become one of the most powerful tools in modern science.

Because epigenetic marks can be reversible and highly dependent on context, they serve as strong biomarkers for disease susceptibility [38]. Genomic and epigenomic datasets are inherently high-dimensional, typically comprising millions of features per individual. The nonlinear interactions and complex patterns within this data are likely to make traditional statistical methods ineffective. The ability to classify epigenetic states - not only across different cell types and tissues throughout the body but also in predicting an individual's future disease risk — is where AI can be most beneficial [39,40].

Both fields are merging and transforming medicine as well. Combining AI-driven analytics with epigenetic data is now close to predicting who will develop anything from cancer and heart problems to lung disease, sometimes decades before their symptoms appear.

## The Molecular Memory of the Genome

Variables such as the environment and genetic factors may influence epigenetic imprinting mechanisms. Of particular importance is the observation that some of these marks persist during gametogenesis or early embryogenesis. Such modifications pass a person's legacy across generations.

The impact of this on disease inheritance and risk is clearly shown in models where methylation patterns in sperm are influenced by smoking fathers. The placental development of the next generation may be negatively affected by in utero damage, leading to a higher risk of respiratory problems later in life for those offspring [37,41,42]

AI algorithms can analyse DNA methylation landscapes to identify early indicators of respiratory diseases [e.g., asthma or COPD] when no symptoms are yet detectable [38,43]. Additionally, machine learning models can predict histone modification states and provide insights into gene expression patterns that influence lung function [35,44]. Moreover, advanced deep learning methods can identify abnormal miRNA and lncRNA signatures, which act as predictive biomarkers for pulmonary inflammation and tissue remodelling [45]

## Disease Prediction

### *Respiratory Disease Prediction*

The concept of epigenetic memory provides a robust framework for understanding how tobacco exposure leaves lasting molecular epigenetic markers that are transmitted across generations, with consequences for the respiratory health of subsequent generations [34]. Recent research has shown that changes to the epigenome in the germ line [such as defects in DNA methylation or histone modification] can avoid reprogramming during fertilisation and contribute to the persistence of disease-related signatures. These findings complement numerous pieces of evidence indicating that tobacco-smoking-induced alterations to the epigenome of sperm result in changed function of the placenta and the viability of trophoblast cells, which directly affect respiratory vulnerability in utero [46].

At the same time, artificial intelligence offers unique synergies that enable the integration of high-dimensional epigenetic datasets, such as methylation landscapes, and is capable of identifying predictive biomarkers for lung dysfunction [38]. Today's learning methods can identify individuals at risk for multiple respiratory diseases, and even early-age lung cancer, with unprecedented accuracy, paving the way for preventative treatments that might reduce the transgenerational burden of tobacco [45,47].

## Neurological Disease Prediction

Epigenetic modifications are increasingly recognised for their role in regulating gene expression in the brain. Abnormalities in these mechanisms have been associated with various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and others [48,49].

Nicotine, one of the most common psychoactive drugs, exerts a powerful influence on the brain's reward system, and increasing evidence suggests an epigenetic basis for the health risks. Chronic nicotine use has been shown to cause histone modifications, especially acetylation, which then influence gene expression patterns in reward regions like the nucleus accumbens. These epigenetic changes result in the upregulation of genes such as FosB, a key transcription factor involved in neuronal plasticity, leading to heightened reactivity of dopaminergic circuits to future stimuli. Kandel & Kandel highlight in their study how epigenetic modifications within the NAcc [nucleus accumbens] may contribute to dysregulated dopamine signalling, supporting increased reward-responsiveness and providing a neurobiological foundation for nicotine as a gateway drug [50].

Additionally, adolescence is a crucial period characterised by increased vulnerability. Dao et al. examined nicotine exposure during this developmental stage and identified changes in the dopamine system, along with lasting effects on reward-related behaviour [51].

In light of these findings, we can affirm that early life nicotine exposure reprograms the nervous system through epigenetic mechanisms, while enhancing the brain's reward system and posing risks to dopaminergic pathways.

#### *From Prediction to Prevention*

AI offers a practical promise in epigenetics: prediction can lead to prevention. AI is used in oncology, for instance, to classify tumours based on their methylation profiles, which can aid in identifying the most effective treatment.

Building on the idea that AI can turn epigenetic prediction into prevention, recent advancements have demonstrated its significance in early-life prediction and prevention. AI models utilising epigenetic data can identify individuals with heritable epigenetic damage caused by maternal smoking, enabling early preventative measures to lower the risk of respiratory issues in children of these mothers.

A study by Rauschert et al. developed a DNA methylation score that effectively indicates fetal exposure to maternal smoking during pregnancy. This risk score surpassed previous models, demonstrating the potential of epigenetic biomarkers for predicting the health effects of maternal smoking [52].

Furthermore, Zakarya et al. examined the impacts of in utero exposure to maternal cigarette smoke [MCS], environmental tobacco smoke [ETS], and electronic cigarette vapour [ECV] on fetal and postnatal lung function, as well as epigenetic modifications. Their findings emphasise the importance of considering all forms of tobacco exposure when assessing respiratory health risks in offspring [53].

Together, these studies underscore the potential of integrating artificial intelligence with epigenetic biomarkers to forecast infants at risk due to maternal smoking.

## **Challenges and Ethical Considerations**

Introducing AI into epigenetic risk prediction has significant scalable clinical potential, but it also raises equally critical ethical questions. One aspect of this is especially notable, as AI systems may perpetuate disparities if specific ancestries are excluded from the training data [54].

Clinically, the ultra-rapid sequencing studies – such as Ashley's work at Stanford that demonstrated genome analysis could be completed within 24 hours – not only highlight its transformational potential but also raise ethical concerns: from rushed consent to opaque decision-making by automated systems [55]. Ashley emphasises the need for transparency, clarity about scope, and family-inclusive counselling, especially because epigenetic risk often impacts future generations [56].

Consequently, integrating AI with epigenetic medicine demands a framework founded on dynamic consent, privacy-protecting governance, and fairness assessments [54,57–62].

## Future Perspectives

The integration of epigenetics and AI into everyday life will revolutionise the way we predict and prevent diseases. New techniques, such as EPIC-Seq, may enable non-invasive, high-resolution profiling of gene expression through DNA sequencing, offering an opportunity for early detection of diseases affecting the respiratory system, and not only [63].

Moreover, progress in longitudinal AI models, such as multi-mean Gaussian processes, enables the prediction of DNA methylation changes over time, supporting the prediction of disease course and the development of personalised interventions [64].

Furthermore, the application of AI to epigenetic data is also shaping precision medicine, particularly in the field of cancer care. According to the AI algorithms currently employed to guide the use of genetic risk factors, the goal should be to progress toward disease screening, thereby enabling the forecasting of patient outcomes [65,66].

These technological advances showcase the potential of AI-powered epigenetic research to revolutionise our understanding and treatment of respiratory diseases, especially those impacted by environmental factors.

## Discussion

Alongside a substantial body of evidence from human and animal studies, the conclusions in this current study represent a significant advance in our understanding of how environmental exposure [e.g., cigarette smoke] affects the respiratory tract. For decades, the prevailing view was that diseases like asthma and chronic obstructive pulmonary disease could be almost entirely explained by two factors: either a person inherited a genetic predisposition or they were directly exposed to harmful environmental substances. However, recent discoveries in the emerging field of transgenerational epigenetic inheritance are challenging these simplistic perspectives.

Exposure is central to this discussion because harmful substances rarely stay only in the place where they first enter the body. Instead, they spread and cause effects throughout the entire organism. They can leave behind biological marks at the level of the genome — marks that do not alter the DNA itself but that influence how genes are turned on or off. These marks, called epigenetic modifications, can last long after the original exposure has disappeared and, troublingly, can be passed between generations. There are many examples of these prints above the genome, but one of the most well-known is DNA methylation.

## The Importance of DNA Methylation

Lately, new high-throughput studies have reinforced the association between methylation and pulmonary phenotypes. A key finding has emerged around the AHRR gene: the methylation site cg05575921 in this particular gene has been identified as the most reliable molecular signature of tobacco smoke exposure, enabling the addition of precision to risk models for lung cancer screening[69]. Building on this information, recent epigenome-wide studies confirm that respiratory AHRR methylation is not merely a fixed marker of exposure. It also has the power of showing a clear dose-response pattern with the amount smoked, has intermediate levels in ex-smokers, and, surprisingly, can partially reverse over time. More interesting is how lifestyle factors, such as physical activity and sleep, influence the rate of epigenetic recovery, emphasising their potential as crucial biomarkers. Also, these indicators can monitor changes in respiratory risk after the smoker has quit tobacco[70].

In humans, a direct analysis of the epigenome in lung tissue has shown that smoking produces a distinct methylation signature in the lung. Stueve et al. identified a strong correlation between lung and blood methylation signatures and further documented lung-specific smoke-inducible enhancers.

Among the top-ranking loci [71,72], AHRR has proven to be a significant, universally smoke-responsive site in the lung tissue, indicating local regulatory activity relevant for pulmonary inflammation [73].

## The HUNT Study

Through a comprehensive investigation within the HUNT Study, Sun et al. [2021] examined the effects of tobacco on DNA methylation and the potential implications for pulmonary health. They performed repeated measurements of DNA methylation over twenty years. The findings indicated that smoking causes lasting changes in the blood epigenome and that these modifications remain stable over time. This emphasises the enduring impact of tobacco on the epigenetic landscape. The researchers employed Mendelian randomisation to assess causal relationships, finding that smoking affects changes in DNA methylation. These findings highlight the complexity of genetic regulation and demonstrate how epigenetic profiling can be utilised to monitor environmental exposures. This research opens new avenues for investigating the intricate relationship between lifestyle factors, epigenetic modifications, and disease development, laying the groundwork for future preventive and predictive strategies in medicine [74].

## The future with the GrimAge clock

Nowadays, we can confidently say that the use of DNA methylation-based biomarkers, particularly a new technology called GrimAge, which is an epigenetic clock, has significantly enhanced our understanding of biological ageing. GrimAge is a composite biomarker consisting of DNA methylation-based surrogates for plasma proteins, cumulative smoking exposure, and predictions of lifespan and healthspan. It demonstrates superior predictive ability for diseases and cancer compared to other epigenetic clocks. This improvement results from including DNA methylation predictors of physiological risk factors and stressors, such as adrenomedullin, C-reactive protein, plasminogen activator inhibitor-1, and growth differentiation factor 15, into the algorithm [75]. A newer version, GrimAge version 2, incorporates additional markers and is more effective at predicting multiple health-related outcomes, including type 2 diabetes and visceral fat, making it a more accurate measure of biological age [76].

The integration of artificial intelligence into epigenetic clocks broadens their range of applications. Complex methylation data, along with lifestyle and health information, can be analysed by AI models to generate personalised predictions of biological age and to assess health risks. For example, AI-based models, such as ExplaiNable BioLogical-ENABL-Age, have been developed to forecast epigenetic age acceleration by considering modifiable factors, including patient histories and environmental exposures. These advances enable a more detailed understanding of the ageing process and support the development of interventions aimed at preventing age-related diseases [77,78]. It has also been reported that smoking influences epigenetic age acceleration in lung bronchoalveolar lavage [BAL] cells. In this context, GrimAge indicates smoking-related acceleration of biological age in lung cells. Furthermore, the specific effect was observed in patients with multiple sclerosis: scientists demonstrated transcriptional differences between the cells of smokers and non-smokers. This highlights the tissue-specific effects of smoking on epigenetic ageing and emphasises the importance of considering tissue-specific biomarkers in ageing research [79,80].

Regarding this aspect, the emergence of transgenerational epigenetic inheritance challenges the conventional notion that diseases such as asthma and COPD are entirely genetically determined or directly caused by environmental factors. For instance, the work conducted by Rehan et al. clearly demonstrates the transgenerational impact of in-utero nicotine exposure in generation F0, leading to increased disease susceptibility across subsequent generations. Because of this epigenetic legacy, the effect of smoking is now known to extend far beyond the smoker, putting the lives of unborn family members as well as individuals in proximity at risk.

Whereas mutations become permanent changes to the DNA sequence, epigenetic changes can be reversed but remain stable enough to be passed on through cell divisions and even down the germline to the next generation. The effects of such persistence are significant. It is also a response to the fact that what used to be regarded as a personal risk factor, smoking, is now widely and correctly seen as something that is imposed on others, apart from the individual smoker. The harm takes hold in the family tree, affecting the health of future generations as well. Therefore, the impacts are not just personal but societal – entire populations could face a greater burden of disease as a result of their ancestors being exposed to noxious substances.

In addition to addressing the risk of current adverse health effects, public health efforts should highlight the long-term consequences of tobacco use. The finding that epigenetic changes are somewhat reversible is an excellent target for intervention, since it means that smokers could potentially avoid the health downsides of smoking through drugs or lifestyle changes. This paves the way for interventions that might mitigate the deleterious effects - not just for smokers themselves, but for their children and grandchildren.

### **Past, Present and Future Potential**

The knowledge we have today about genes and their influence on our lives was made possible through the Human Genome Project [HGP], which started in 1990 and finished in 2003. Its main goal was to tackle the challenges of modern biology by creating a complete reference sequence of human DNA. This transformed the landscape of biological research, affecting how it is funded, organised, and carried out. A draft of the genome was published by 2000, and a nearly complete sequence was available within the following three years [81]. By providing a reference genome, the HGP laid a foundation for many future genomic initiatives [82]. The project also raised important ethical and philosophical questions. From the start, it had implications not only as a scientific milestone but also as a real contribution to humanity [83]. This sequenced genome provided a detailed “blueprint” of the DNA code; however, the machinery that determines when and where individual genes are activated remained to be clarified.

To address this gap, scientists initiated the Human Epigenome Project [HEP] in the 2000s. This initiative aimed to systematically annotate the methylation status of the entire epigenome as a logical extension of the HGP. Central to this approach was an emphasis on epigenetic regulation, which sought to understand how identical DNA sequences could give rise to diverse cellular phenotypes through chemical modifications[84].

The significance of this lies in recognising that genetics alone cannot explain the complexity of biological regulation, and these epigenetic modifications are essential for gene regulation. The Human Epigenome Project, therefore, marked the start of a new era in genomics research. This development plays a vital role in scientists' work today and will continue to serve as the foundation for future discoveries [85].

The role of artificial intelligence in this field is more than just a technological addition: it represents the next stage of predictive and preventive medicine. Epigenomic information is highly multidimensional, comprising millions of marks, and traditional statistics cannot handle it all. Consequently, with millions of data points per individual, conventional statistical methods often fail to work with this epigenomic data. Therefore, AI helps interpret these vast data collections, aiming to identify patterns and epigenetic markers associated with disease.

However, now people can identify which diseases they are predisposed to before the first symptoms appear. By combining AI-based epigenomic analyses with clinical data, one can not only create personalised treatment plans but also predict how a disease will progress over time. In other words, medicine could finally move away from its traditional reactive approach of waiting for symptoms to develop and then treating them, towards a proactive approach where doctors can intervene before a disease even manifests.

Put, this could mean that individuals at high, medium, or even low risk of developing asthma, COPD, or cancer based on their genetic and epigenetic signature could be identified early, monitored

closely, and given targeted advice or treatments to reduce the risk before illness ever manifests. Over time, doctors will have access to the complete genetic and epigenetic profiles of all their patients. This will enable them not only to make accurate diagnoses based on current symptoms but also to determine the precise medication and dosages for each person. With AI-enabled analysis of the data, doctors will be guided on how to care for their patients, ensuring the correct prescriptions are issued, which will save time, reduce suffering, and improve patient outcomes.

Given the above, when AI is introduced into genetic and epigenetic medicine, it will make health a more personalised science. Doctors will not be confined to coming up with guidelines or population-level statistics. Instead, they will be able to view the patient as a special case of unique biology and circumstance. In the future, we hope that the role of medicine will shift towards enhancing survival, refining the quality of life, and providing protection not only for the patient but also for their descendants, thereby addressing the potentially severe repercussions of exposure to detrimental factors.

## Conclusions

Cigarette smoking has a profound and enduring effect on respiratory health, impacting not only the individual directly exposed but also offspring in subsequent generations through numerous epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNA regulation [1–37].

The cumulative human evidence and animal models, particularly the work of Rehan et al., suggest that exposure to environmental factors, even before conception or during pregnancy, carries transgenerational risks of lung disease and altered gene expression patterns [34,35]. These molecular changes serve as a memory of environmental trauma, maintaining an increased risk of disease in the offspring of parents who were themselves exposed.

The combination of high-throughput genomic and epigenomic profiling can now be performed alongside AI, providing not only an unprecedented ability to interpret complex data but also new opportunities for identifying predictive biomarkers or modelling disease risk at the individual level [38–40,42–47].

Such an amalgam of AI and epigenetics not only enables early detection but also offers the potential for precise prevention of respiratory diseases, including asthma, COPD, and lung cancer, which affect multiple generations. It shields people of all ages from the heavy burden caused by tobacco inheritance. [45–51].

Ultimately, understanding and addressing the epigenetic effects of smoking shifts us from a reactive to a proactive approach to prevention, one that emphasises molecular understanding as a basis, alongside ethical responsibility. The translational potential of AI-driven epigenetic analysis envisages a future where predictive medicine is practised across generations, offering a scientifically informed method to reduce respiratory illnesses and improve public health. [67,68].

## Abbreviations

*ADAM33* – A Disintegrin And Metalloprotease 33

*AHRR* – Aryl-Hydrocarbon Receptor Repressor

*AI* – Artificial Intelligence

*BAL* – Bronchoalveolar Lavage

*cg05575921* – CpG site 05575921 [in *AHRR* gene]

*COPD* – Chronic Obstructive Pulmonary Disease

*DNA* – Deoxyribonucleic Acid

*ECV* – Electronic Cigarette Vapour

*EPIC-Seq* – Enhanced Pooled ImmunoCapture Sequencing

*ETS* – Environmental Tobacco Smoke  
*FosB* – FBJ Murine Osteosarcoma Viral Oncogene Homolog B  
*H3* – Histone H3  
*HEP* – Human Epigenome Project  
*HGP* – Human Genome Project  
*IL13* – Interleukin 13  
*lncRNA* – Long Non-Coding RNA  
*MCS* – Maternal Cigarette Smoke  
*miR-21* – MicroRNA 21  
*miR-223* – MicroRNA 223  
*miRNA* – MicroRNA  
*NAcc* – Nucleus Accumbens  
*PAH* – Polycyclic Aromatic Hydrocarbons  
*PPAR $\gamma$*  – Peroxisome Proliferator-Activated Receptor- $\gamma$   
*RNA* – Ribonucleic Acid  
*SERPINA1* - Serpin Peptidase Inhibitor, Clade A, Member 1

## Reference

1. WHO Report on the Global Tobacco Epidemic 2021 : Addressing New and Emerging Products. World Health Organization; 2021.
2. Skinner MK. Environmental epigenomics and disease susceptibility. *EMBO Rep.* 2011 Jul 1;12[7]:620–2.
3. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet.* 2012 May 29;13[7]:484–92.
4. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. *Science.* 2001 Aug 10;293[5532]:1089–93.
5. Breton C V, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. *Am J Respir Crit Care Med.* 2009 Sep 1;180[5]:462–7.
6. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. *Am J Hum Genet.* 2016 Apr 7;98[4]:680–96.
7. Zhang S, Jin J, Xu B, Zheng Q, Mou H. The relationship between epigenetic biomarkers and the risk of diabetes and cancer: a machine learning modelling approach. *Front Public Health.* 2025;13:1509458.
8. Rauschert S, Raubenheimer K, Melton PE, Huang RC. Machine learning and clinical epigenetics: a review of challenges for diagnosis and classification. *Clin Epigenetics.* 2020 Apr 3;12[1]:51.
9. Burton NO, Greer EL. Multigenerational epigenetic inheritance: Transmitting information across generations. *Semin Cell Dev Biol.* 2022 Jul;127:121–32.
10. Campagna MP, Xavier A, Lechner-Scott J, Maltby V, Scott RJ, Butzkueven H, et al. Epigenome-wide association studies: current knowledge, strategies and recommendations. *Clin Epigenetics.* 2021 Dec 4;13[1]:214.
11. Brasil S, Neves CJ, Rijoff T, Falcão M, Valadão G, Videira PA, et al. Artificial Intelligence in Epigenetic Studies: Shedding Light on Rare Diseases. *Front Mol Biosci.* 2021;8:648012.
12. Nishitani S, Smith AK, Tomoda A, Fujisawa TX. Data science using the human epigenome for predicting multifactorial diseases and symptoms. *Epigenomics.* 2024 Mar;16[5]:273–6.
13. Vinciguerra M. The Potential for Artificial Intelligence Applied to Epigenetics. *Mayo Clinic proceedings Digital health.* 2023 Dec;1[4]:476–9.
14. P5 eHealth: An Agenda for the Health Technologies of the Future. Springer; 2020.
15. Tobacco smoking and involuntary smoking. World Health Organization; 2004.

16. Keshawarz A, Joehanes R, Guan W, Huan T, DeMeo DL, Grove ML, et al. Longitudinal change in blood DNA epigenetic signature after smoking cessation. *Epigenetics*. 2022 Oct;17[10]:1098–109.
17. Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev*. 2002 Jan 1;16[1]:6–21.
18. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. *PLoS One*. 2013;8[5]:e63812.
19. Suter MA, Abramovici AR, Griffin E, Branch DW, Lane RH, Mastrobattista J, et al. In utero nicotine exposure epigenetically alters fetal chromatin structure and differentially regulates transcription of the glucocorticoid receptor in a rat model. *Birth Defects Res A Clin Mol Teratol*. 2015 Jul;103[7]:583–8.
20. MALLAR BHATTACHARYA. Airway architect Adam33 in asthma. *Science Translational Medicine*. 2016 Aug 17;8[352]:130.
21. Nicodemus-Johnson J, Naughton KA, Sudi J, Hogarth K, Naurekas ET, Nicolae DL, et al. Genome-Wide Methylation Study Identifies an IL-13-induced Epigenetic Signature in Asthmatic Airways. *Am J Respir Crit Care Med*. 2016 Feb 15;193[4]:376–85.
22. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. *Am J Respir Crit Care Med*. 2012 Feb 15;185[4]:373–81.
23. Yang I V, Schwartz DA. Epigenetic mechanisms and the development of asthma. *J Allergy Clin Immunol*. 2012 Dec;130[6]:1243–55.
24. Breton C V, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. *Am J Respir Crit Care Med*. 2009 Sep 1;180[5]:462–7.
25. Mahon GM, Koppelman GH, Vonk JM. Grandmaternal smoking, asthma and lung function in the offspring: the Lifelines cohort study. *Thorax*. 2021 May;76[5]:441–7.
26. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res*. 2011 Mar;21[3]:381–95.
27. Sundar IK, Nevid MZ, Friedman AE, Rahman I. Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer. *J Proteome Res*. 2014 Feb 7;13[2]:982–96.
28. Nilsson EE, Sadler-Riggelman I, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of disease. *Environ Epigenet*. 2018 Apr;4[2]:dvy016.
29. Russ R, Slack FJ. Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis. *Pulm Med*. 2012;2012:791234.
30. Graff JW, Powers LS, Dickson AM, Kim J, Reisetter AC, Hassan IH, et al. Cigarette smoking decreases global microRNA expression in human alveolar macrophages. *PLoS One*. 2012;7[8]:e44066.
31. Tando Y, Matsui Y. Inheritance of environment-induced phenotypic changes through epigenetic mechanisms. *Environ Epigenet*. 2023;9[1]:dvd008.
32. Di HK, Gan Y, Lu K, Wang C, Zhu Y, Meng X, et al. Maternal smoking status during pregnancy and low birth weight in offspring: systematic review and meta-analysis of 55 cohort studies published from 1986 to 2020. *World J Pediatr*. 2022 Mar;18[3]:176–85.
33. Küpers LK, Xu X, Jankipersadsing SA, Vaez A, la Bastide-van Gemert S, Scholtens S, et al. DNA methylation mediates the effect of maternal smoking during pregnancy on the birthweight of the offspring. *Int J Epidemiol*. 2015 Aug;44[4]:1224–37.
34. Rehan VK, Liu J, Naeem E, Tian J, Sakurai R, Kwong K, et al. Perinatal nicotine exposure induces asthma in second-generation offspring. *BMC Med*. 2012 Oct 30;10:129.
35. Leslie FM. Multigenerational epigenetic effects of nicotine on lung function. *BMC Med*. 2013 Feb 4;11:27.
36. Bhadsavle SS, Golding MC. Paternal epigenetic influences on placental health and their impacts on offspring development and disease. *Front Genet*. 2022;13:1068408.
37. Vlachou M, Kyrkou G, Georgakopoulou VE, Kapetanaki A, Vivilaki V, Spandidos DA, et al. Smoke signals in the genome: Epigenetic consequences of parental tobacco exposure [Review]. *Biomed Rep*. 2025 Sep;23[3]:146.
38. Holder LB, Haque MM, Skinner MK. Machine learning for epigenetics and future medical applications. *Epigenetics*. 2017 Jul 3;12[7]:505–14.

39. Liu J, Li J, Wang H, Yan J. Application of deep learning in genomics. *Sci China Life Sci.* 2020 Dec;63[12]:1860–78.
40. Tahir M, Norouzi M, Khan SS, Davie JR, Yamanaka S, Ashraf A. Artificial intelligence and deep learning algorithms for epigenetic sequence analysis: A review for epigeneticists and AI experts. *Comput Biol Med.* 2024 Dec;183:109302.
41. Ritzmann F, Brand M, Bals R, Wegmann M, Beisswenger C. Role of Epigenetics in Chronic Lung Disease. *Cells.* 2025 Feb 10;14[4].
42. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res.* 2011 Mar;21[3]:381–95.
43. Li DD, Chen T, Ling YL, Jiang Y, Li QG. A Methylation Diagnostic Model Based on Random Forests and Neural Networks for Asthma Identification. *Comput Math Methods Med.* 2022;2022:2679050.
44. Vinciguerra M. The Potential for Artificial Intelligence Applied to Epigenetics. *Mayo Clinic proceedings Digital health.* 2023 Dec;1[4]:476–9.
45. Gomes B, Ashley EA. Artificial Intelligence in Molecular Medicine. *N Engl J Med.* 2023 Jun 29;388[26]:2456–65.
46. Kitaba NT, Knudsen GTM, Johannessen A, Rezwani FI, Malinowski A, Oudin A, et al. Fathers' preconception of smoking and offspring DNA methylation. *Clin Epigenetics.* 2023 Aug 31;15[1]:131.
47. Natalie Crowley. AI Detects Disease Clues from DNA Methylation Data. *What is Epigenetics.* 2023 Oct 1;
48. Grezenko H, Ekhatov C, Nwabugwu NU, Ganga H, Affaf M, Abdelaziz AM, et al. Epigenetics in Neurological and Psychiatric Disorders: A Comprehensive Review of Current Understanding and Future Perspectives. *Cureus.* 2023 Aug;15[8]:e43960.
49. Kuehner JN, Bruggeman EC, Wen Z, Yao B. Epigenetic Regulations in Neuropsychiatric Disorders. *Front Genet.* 2019;10:268.
50. Kandel DB, Kandel ER. A molecular basis for nicotine as a gateway drug. *N Engl J Med.* 2014 Nov 20;371[21]:2038–9.
51. Dao JM, McQuown SC, Loughlin SE, Belluzzi JD, Leslie FM. Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism. *Neuropsychopharmacology.* 2011 Jun;36[7]:1319–31.
52. Rauschert S, Melton PE, Heiskala A, Karhunen V, Burdge G, Craig JM, et al. Machine Learning-Based DNA Methylation Score for Fetal Exposure to Maternal Smoking: Development and Validation in Samples Collected from Adolescents and Adults. *Environ Health Perspect.* 2020 Sep;128[9]:97003.
53. Zakarya R, Adcock I, Oliver BG. Epigenetic impacts of maternal tobacco and e-vapour exposure on the offspring lung. *Clin Epigenetics.* 2019 Feb 19;11[1]:32.
54. Fernando A, Kondrup E, Cheung K, Uberoi D, Joly Y. Still using genetic data? A comparative review of Canadian life insurance application forms before and after the GND. *FACETS.* 2024 Jan 1;9:1–10.
55. Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al. Inferring gene expression from cell-free DNA fragmentation profiles. *Nat Biotechnol.* 2022 Apr;40[4]:585–97.
56. Leroy A, Teh AL, Dondelinger F, Alvarez MA, Wang D. Longitudinal prediction of DNA methylation to forecast epigenetic outcomes. *EBioMedicine.* 2025 May;115:105709.
57. Oliva A, Kaphle A, Reguant R, Sng LMF, Twine NA, Malakar Y, et al. Future-proofing genomic data and consent management: a comprehensive review of technology innovations. *Gigascience.* 2024 Jan 2;13.
58. Teare HJA, Pictor M, Kaye J. Reflections on dynamic consent in biomedical research: the story so far. *Eur J Hum Genet.* 2021 Apr;29[4]:649–56.
59. Brauneck A, Schmalhorst L, Weiss S, Baumbach L, Völker U, Ellinghaus D, et al. Legal aspects of privacy-enhancing technologies in genome-wide association studies and their impact on performance and feasibility. *Genome Biol.* 2024 Jun 13;25[1]:154.
60. The Genetic Information Nondiscrimination Act [GINA]. American Society of Human Genetics.
61. Marvin van Bekkum, Frederik Zuiderveen Borgesius, Tom Heskes. AI, insurance, discrimination and unfair differentiation: an overview and research agenda. *Taylor&Francis.* 2025 Mar 11;177–204.
62. Gorzynski JE, Goenka SD, Shafin K, Jensen TD, Fisk DG, Grove ME, et al. Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting. *N Engl J Med.* 2022 Feb 17;386[7]:700–2.

63. Alsaedi S, Ogasawara M, Alarawi M, Gao X, Gojobori T. AI-powered precision medicine: utilizing genetic risk factor optimization to revolutionize healthcare. *NAR Genom Bioinform.* 2025 Jun;7[2]:lqaf038.
64. Zhang S, Jin J, Xu B, Zheng Q, Mou H. The relationship between epigenetic biomarkers and the risk of diabetes and cancer: a machine learning modelling approach. *Front Public Health.* 2025;13:1509458.
65. Rauschert S, Raubenheimer K, Melton PE, Huang RC. Machine learning and clinical epigenetics: a review of challenges for diagnosis and classification. *Clin Epigenetics.* 2020 Apr 3;12[1]:51.
66. Burton NO, Greer EL. Multigenerational epigenetic inheritance: Transmitting information across generations. *Semin Cell Dev Biol.* 2022 Jul;127:121–32.
67. Arefeen MA, Nimi ST, Rahman MS, Arshad SH, Holloway JW, Rezwan FI. Prediction of Lung Function in Adolescence Using Epigenetic Aging: A Machine Learning Approach. *Methods Protoc.* 2020 Nov 9;3[4].
68. Krauss-Etschmann S, Meyer KF, Dehmel S, Hylkema MN. Inter- and transgenerational epigenetic inheritance: evidence in asthma and COPD? *Clin Epigenetics.* 2015;7[1]:53.
69. Jacobsen KK, Schnohr P, Jensen GB, Bojesen SE. AHRR [cg05575921] Methylation Safely Improves Specificity of Lung Cancer Screening Eligibility Criteria: A Cohort Study. *Cancer Epidemiol Biomarkers Prev.* 2022 Apr 1;31[4]:758–65.
70. Tsai PC, Glastonbury CA, Eliot MN, Bollepalli S, Yet I, Castillo-Fernandez JE, et al. Smoking induces coordinated DNA methylation and gene expression changes in adipose tissue with consequences for metabolic health. *Clin Epigenetics.* 2018 Oct 20;10[1]:126.
71. Stueve TR, Li WQ, Shi J, Marconett CN, Zhang T, Yang C, et al. Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. *Hum Mol Genet.* 2017 Aug 1;26[15]:3014–27.
72. Li JL, Jain N, Tamayo LI, Tong L, Jasmine F, Kibriya MG, et al. The association of cigarette smoking with DNA methylation and gene expression in human tissue samples. *Am J Hum Genet.* 2024 Apr 4;111[4]:636–53.
73. Chen Q, Nwozor KO, van den Berge M, Slebos DJ, Faiz A, Jonker MR, et al. From Differential DNA Methylation in COPD to Mitochondria: Regulation of AHRR Expression Affects Airway Epithelial Response to Cigarette Smoke. *Cells.* 2022 Oct 29;11[21].
74. Sun YQ, Richmond RC, Suderman M, Min JL, Battram T, Flatberg A, et al. Assessing the role of genome-wide DNA methylation between smoking and risk of lung cancer using repeated measurements: the HUNT study. *Int J Epidemiol.* 2021 Nov 10;50[5]:1482–97.
75. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging.* 2019 Jan 21;11[2]:303–27.
76. Lu AT, Binder AM, Zhang J, Yan Q, Reiner AP, Cox SR, et al. DNA methylation GrimAge version 2. *Aging.* 2022 Dec 14;14[23]:9484–549.
77. Zhang Q. An interpretable biological age. *Lancet Healthy Longev.* 2023 Dec;4[12]:e662–3.
78. Qiu W, Chen H, Kaeberlein M, Lee SI. Explainable BioLogical Age [ENABL Age]: an artificial intelligence framework for interpretable biological age. *Lancet Healthy Longev.* 2023 Dec;4[12]:e711–23.
79. Song MA, Mori KM, McElroy JP, Freudenheim JL, Weng DY, Reisinger SA, et al. Accelerated epigenetic age, inflammation, and gene expression in lung: comparisons of smokers and vapers with non-smokers. *Clin Epigenetics.* 2023 Oct 11;15[1]:160.
80. Klose D, Needhamsen M, Ringh M V, Hagemann-Jensen M, Jagodic M, Kular L. Smoking affects epigenetic ageing of lung bronchoalveolar lavage cells in Multiple Sclerosis. *Mult Scler Relat Disord.* 2023 Nov;79:104991.
81. Human Genome Project: The most important biomedical research undertaking of the 20th Century. National Human Genome Research Institute. 2024 Jun 13;
82. Hood L, Rowen L. The Human Genome Project: big science transforms biology and medicine. *Genome Med.* 2013;5[9]:79.
83. Kabata F, Thaldar D. The human genome as the common heritage of humanity. *Front Genet.* 2023;14:1282515.
84. Bradbury J. Human epigenome project--up and running. *PLoS Biol.* 2003 Dec;1[3]:E82.

85. Eckhardt F, Beck S, Gut IG, Berlin K. Future potential of the Human Epigenome Project. *Expert Rev Mol Diagn.* 2004 Sep;4[5]:609–18.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author[s] and contributor[s] and not of MDPI and/or the editor[s]. MDPI and/or the editor[s] disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.